NeuroScientific Biopharmaceuticals (ASX:NSB) has appointed Robert McKenzie as Non-Executive Chairman, effective Friday, June 27, following the completion of its acquisition of Isopogen WA, holder of StemSmart, a patented stem cell technology, according to a same-day filing with the Australian bourse.
McKenzie succeeds outgoing Non-Executive Chairman Christopher Ntoumenopoulos and will receive 5 million unquoted options.
exercisable at AU$0.07 each and expiring three years from the date of issue, the filing said.
The company also appointed Marian Sturm as Chief Scientific Officer.
Shares of the company rose 4% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.